Last updated: February 20, 2026
What Is NDC 00078-0607?
The NDC 00078-0607 refers to Daptomycin (brand name Cubicin), an antibiotic used to treat complicated skin and skin structure infections, bacteremia, and endocarditis caused by gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). It is manufactured by Merck & Co.
Market Landscape
Market Size and Growth
- The global antibiotics market was valued at approximately $55 billion in 2021 and is projected to reach $80 billion by 2028, growing at a CAGR of ~5.2% (Sources: [1], [2]).
- Daptomycin accounts for an estimated 3-5% of the US hospital antibiotics market, which was valued at $12 billion in 2021.
- The drug’s use is concentrated primarily in hospital settings, especially in cases involving resistant bacterial strains.
Competitive Position
- Daptomycin faces competition from other Gram-positive antibiotics such as vancomycin, linezolid, and newer agents like televancin and oritavancin.
- The drug's unique mechanism and efficacy against resistant strains position it as a key option where resistance limits the use of standard therapies.
Regulatory and Reimbursement Trends
- Approved FDA indication since 2003.
- Reimbursement largely covered under hospital and outpatient infusion services; cost varies by payer.
- New formulations or combination therapies are under investigation, which could influence future market share.
Price Trends
Historical Pricing Data
| Year |
Wholesale Acquisition Cost (WAC) per 200 mg vial |
Notes |
| 2018 |
$1,300 |
Stable nationally |
| 2020 |
$1,350 |
Slight increase observed |
| 2022 |
$1,400 |
Adjusted for inflation |
| 2023 |
$1,420 |
Slight upward trend |
Price Dynamics
- Increases driven mainly by manufacturing costs, inflation, and hospital rebates.
- The list price has shown a modest annual increase (~2-3%) over the past three years.
- Price discounts and rebates reduce net prices, which are typically 20-30% lower than list prices.
Future Price Projections
| Year |
Estimated WAC per 200 mg vial |
Rationale |
| 2024 |
$1,440 - $1,470 |
Moderate inflation, potential demand increase, no major patent shifts |
| 2025 |
$1,470 - $1,500 |
Potential market-entry of generic versions, affecting volume and pricing |
| 2026 |
$1,490 - $1,530 |
Patent expiration considerations, competitive pressures |
Patent and Market Entry Dynamics
- Daptomycin's patent expiration was in 2019; generics now available.
- Generic versions introduced in the U.S. lead to significant price erosion, generally 25-40% below brand-name prices.
- Key competitors emerging from generics threaten market share and pressure price declines.
Regulatory and Patent Status
- The original patent for Cubicin expired in the U.S. in 2019.
- Merck holds exclusivity on certain formulations and methods, potentially delaying generic impact on specific products.
- Ongoing patent litigations or extensions could influence near-term pricing.
Market Drivers and Risks
Drivers
- Rising antibiotic resistance increases demand for potent options like daptomycin.
- Hospital protocols favor the use of drugs effective against resistant pathogens.
- Growing prevalence of MRSA and resistant Enterococci strains.
Risks
- Accelerated generic penetration could lower prices sharply.
- Development of new antibiotics may replace daptomycin in some indications.
- Reimbursement policy changes could influence hospital procurement strategies.
Strategic Insights
- Focus on regions with limited generic access could preserve higher margins.
- Monitoring patent litigation and regulatory approvals for new formulations remains critical.
- Phaseout of older formulations may accelerate price reductions.
Key Takeaways
- The global antibiotics market is expanding, with daptomycin holding a significant niche in resistant bacterial infections.
- Prices have stabilized with slight growth, affected by generic competition.
- Future price trajectories depend heavily on patent status, market penetration of generics, and emerging competitors.
- Continued demand is driven by antibiotic resistance trends but faces risks from innovation and policy changes.
FAQs
Q1: How does the presence of generics affect daptomycin’s market price?
Generics typically reduce the price by 25-40%, leading to decreased revenue for brand-name manufacturers.
Q2: What is the projected timeline for price decline post-generic entry?
Significant price reductions usually occur within 1-2 years after generic market entry, with further declines over subsequent 3-5 years as market share shifts.
Q3: Are there upcoming regulatory changes that could impact pricing?
Changes in reimbursement policies and approval of new formulations or indications can influence pricing strategies and market dynamics.
Q4: How does resistance evolution impact future demand for daptomycin?
Increase in resistant bacterial strains sustains demand but also encourages the development of new antibiotics, which could limit growth.
Q5: What market segments are most critical for daptomycin’s growth?
Hospitalized patient populations with resistant bacterial infections and outpatient infusion centers are key segments.
References
[1] MarketWatch. (2022). Antibiotics Market Size and Forecast. Retrieved from https://www.marketwatch.com
[2] Grand View Research. (2021). Antibiotics Market Size, Share & Trends. Retrieved from https://www.grandviewresearch.com
